Author:
Amunjela Johanna Ndamwena,Tucker Steven John
Funder
University Of Aberdeen College Of Life Sciences and Medicine
Reference38 articles.
1. Estimated Cancer Incidence, Mortality and Prevalence Worldwide in 2012;Globocan,2012
2. An update of the mechanisms of resistance to EGFR-tyrosine kinase inhibitors in breast cancer: gefitinib (iressa™)-induced changes in the expression and nucleo-cytoplasmic trafficking of HER-ligands (review);Ferrer-Soler;Int. J. Mol. Med.,2007
3. The MEK/MAPK pathway is involved in the resistance of breast cancer cells to the EGFR tyrosine kinase inhibitor gefitinib;Normanno;J. Cell. Physiol.,2006
4. Basal subtype and MAPK/ERK kinase (MEK)-phosphoinositide 3-kinase feedback signaling determine susceptibility of breast cancer cells to MEK inhibition;Mirzoeva;Cancer Res.,2009
5. Nuclear EGFR contributes to acquired resistance to cetuximab;Li;Oncogene,2009
Cited by
16 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献